INX IMCD N.V.

IMCD reports 12% EBITA growth in the first three months of 2025

IMCD reports 12% EBITA growth in the first three months of 2025

Rotterdam, The Netherlands (25 April 2025) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2025 results.

HIGHLIGHTS

• Gross profit up by 10% to EUR 325 million (+10% on a constant currency basis)

• Operating EBITA up by 12% to EUR 142 million (+12% on a constant currency basis)

• Free cash flow of EUR 102 million (first three months of 2024: EUR 106 million)

• Cash earnings per share up by 10% to EUR 1.55 (first three months of 2024: EUR 1.41)

Marcus Jordan, CEO: "After 26 years at IMCD, I am excited to take over the role of CEO and very much look forward to continuing the successful growth story of IMCD. We have had a good start to the year, with an increase in operating EBITA to EUR 142 million (+12%) and an increase in cash earnings per share to EUR 1.55 (+10%), compared with Q1 2024. Despite the current volatile tariff discussions and unpredictable market conditions, we remain confident that our diversified business, supported by our advanced digital and supply chain management capabilities, will continue to create value for our stakeholders."

Attachment



EN
25/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMCD N.V.

 PRESS RELEASE

IMCD to acquire TECOM Ingredients to strengthen its offering in the fo...

IMCD to acquire TECOM Ingredients to strengthen its offering in the food & nutrition market in Spain Rotterdam, The Netherlands (16 May 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has signed an agreement to acquire 100% of the shares in TECOM Ingredients S.A. (“TECOM”). Founded in 1996 and headquartered in Molins de Rei, near Barcelona, Spain, TECOM is a recognised distributor of ingredients and additives to the food industry. The company is a trusted partner for customers active in the food...

Quirijn Mulder ... (+2)
  • Quirijn Mulder
  • Stijn Demeester

IMCD/Good start, valuation attractive/BUY

After surprisingly good numbers 1Q25, we believe there is more upside but 1Q has the easiest comp. Also, trade tariffs might disturb the distribution chain of chemicals. Overall, we modestly adjust our estimates for FY25-27, but we do not change our BUY rating. IMCD is in excellent shape in our view – the company's track record in growth, value enhancement and M&A continues, and its strong asset light model is intact. The share price fall since December has led to 18% lower multiples, suggesting...

IMCD NV: 1 director

A director at IMCD NV bought 840 shares at 118.690EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...

Guy Sips ... (+6)
  • Guy Sips
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Lewi

Morning Notes : AALB NA, AD NA, ARCAD NA, SMAR BB, WKL NA, AZE BB, CTP...

: AALB NA, AD NA, ARCAD NA, SMAR BB, WKL NA, AZE BB, CTPNV NA, IMCD NA

Thibault Leneeuw
  • Thibault Leneeuw

IMCD Short-term revisions in light of the uncertainty

In this note we adjust our numbers to reflect the increased uncertainty which results in lower organic growth for FY25 and FY26. While the Gross Profit margin remained robust, OpEx was well above expectations across all regions. Due to these dynamics we lower our forecasted FY25 EBITA by 6% to € 548m. Furthermore, we dive into the divergence with Azelis as this stood out in 1Q25. Our adjustments result in a lower valuation of € 147 per share. Given the upside we maintain our Accumulate recommend...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch